BioTissue Introduces Dual-Tab Design for CAM360 AmnioGraft to Improve Clinical Handling
2 Articles
2 Articles
BioTissue Introduces CAM360 AmnioGraft™ Dual Tabs to Facilitate Membrane Handling
BioTissue announced an update to CAM360 AmnioGraft™ (CAM360 AG), its Cryopreserved Amniotic Membrane (CAM) therapy for mild to moderate ocular surface disease. The new dual-tab design was developed to facilitate handling and preparation for eyecare professionals (ECPs), while preserving the same CAM360 AG tissue and clinical experience clinicians know and trust. …
BioTissue Introduces Dual-Tab Design for CAM360 AmnioGraft to Improve Clinical Handling
Key Takeaways BioTissue has introduced CAM360 AG Dual Tabs to improve handling and preparation of its cryopreserved amniotic membrane therapy The updated product retains the original ringless, hydrated, shelf-stable design and does not require refrigeration The therapy is intended to support ocular surface healing in conditions including dry eye disease, superficial punctate keratitis, and neurotrophic keratitis BioTissue has announced a…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium





